[ { "key": "C9EWBVI7", "version": 275, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/C9EWBVI7", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/C9EWBVI7", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Panayidou et al.", "parsedDate": "2015", "numChildren": 0 }, "data": { "key": "C9EWBVI7", "version": 275, "itemType": "journalArticle", "title": "GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world", "creators": [ { "creatorType": "author", "firstName": "Klea", "lastName": "Panayidou" }, { "creatorType": "author", "firstName": "Sandro", "lastName": "Gsteiger" }, { "creatorType": "author", "firstName": "Gablu", "lastName": "Kilcher" }, { "creatorType": "author", "firstName": "Matthias", "lastName": "Egger" }, { "creatorType": "author", "firstName": "Máximo", "lastName": "Carreras" }, { "creatorType": "author", "firstName": "Orestis", "lastName": "Efthimiou" }, { "creatorType": "author", "firstName": "Thomas P.A.", "lastName": "Debray" }, { "creatorType": "author", "firstName": "Sven", "lastName": "Trelle" }, { "creatorType": "author", "firstName": "Noemi", "lastName": "Hummel" } ], "abstractNote": "", "publicationTitle": "accepted in Research Synthesis Methods", "publisher": "", "place": "", "date": "2015", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "", "citationKey": "", "url": "", "accessDate": "", "PMID": "", "PMCID": "", "ISSN": "", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2014-11-19T09:36:55Z", "dateModified": "2016-06-06T06:09:50Z" } }, { "key": "X4MKIJ7P", "version": 268, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/X4MKIJ7P", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/X4MKIJ7P", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Kobelt", "parsedDate": "2003-02-01", "numChildren": 0 }, "data": { "key": "X4MKIJ7P", "version": 268, "itemType": "journalArticle", "title": "The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study", "creators": [ { "creatorType": "author", "firstName": "G.", "lastName": "Kobelt" } ], "abstractNote": "", "publicationTitle": "Rheumatology", "publisher": "", "place": "", "date": "2003-2-1", "volume": "42", "issue": "2", "section": "", "partNumber": "", "partTitle": "", "pages": "326-335", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1093/rheumatology/keg107", "citationKey": "", "url": "http://www.rheumatology.oupjournals.org/cgi/doi/10.1093/rheumatology/keg107", "accessDate": "2015-03-03T11:23:07Z", "PMID": "", "PMCID": "", "ISSN": "14602172", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-03T11:23:07Z", "dateModified": "2015-03-03T11:23:07Z" } }, { "key": "K2KJC8HN", "version": 267, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/K2KJC8HN", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/K2KJC8HN", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Kobelt et al.", "parsedDate": "2002", "numChildren": 0 }, "data": { "key": "K2KJC8HN", "version": 267, "itemType": "journalArticle", "title": "Modeling the progression of rheumatoid arthritis: A two-country model to estimate costs and consequences of rheumatoid arthritis", "creators": [ { "creatorType": "author", "firstName": "Gisela", "lastName": "Kobelt" }, { "creatorType": "author", "firstName": "Linus", "lastName": "J�nsson" }, { "creatorType": "author", "firstName": "Peter", "lastName": "Lindgren" }, { "creatorType": "author", "firstName": "Adam", "lastName": "Young" }, { "creatorType": "author", "firstName": "Kerstin", "lastName": "Eberhardt" } ], "abstractNote": "", "publicationTitle": "Arthritis & Rheumatism", "publisher": "", "place": "", "date": "09/2002", "volume": "46", "issue": "9", "section": "", "partNumber": "", "partTitle": "", "pages": "2310-2319", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1002/art.10471", "citationKey": "", "url": "http://doi.wiley.com/10.1002/art.10471", "accessDate": "2015-03-03T11:21:14Z", "PMID": "", "PMCID": "", "ISSN": "0004-3591, 1529-0131", "archive": "", "archiveLocation": "", "shortTitle": "Modeling the progression of rheumatoid arthritis", "language": "en", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-03T11:21:14Z", "dateModified": "2015-03-03T11:21:14Z" } }, { "key": "TT472M6F", "version": 287, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/TT472M6F", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/TT472M6F", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "lastModifiedByUser": { "id": 1843087, "username": "sgsteiger", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/sgsteiger", "type": "text/html" } } }, "creatorSummary": "Welsing et al.", "parsedDate": "2001-09", "numChildren": 1 }, "data": { "key": "TT472M6F", "version": 287, "itemType": "journalArticle", "title": "The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis", "creators": [ { "creatorType": "author", "firstName": "P. M.", "lastName": "Welsing" }, { "creatorType": "author", "firstName": "A. M.", "lastName": "van Gestel" }, { "creatorType": "author", "firstName": "H. L.", "lastName": "Swinkels" }, { "creatorType": "author", "firstName": "L. A.", "lastName": "Kiemeney" }, { "creatorType": "author", "firstName": "P. L.", "lastName": "van Riel" } ], "abstractNote": "OBJECTIVE: To investigate the relationship between functional capacity, disease activity, and joint destruction over the course of rheumatoid arthritis (RA).\nMETHODS: The followup data on 378 patients with early RA (duration <1 year), included in an open, prospective study since 1985 at the Department of Rheumatology of the University Medical Center Nijmegen, were used. Functional capacity, disease activity, and joint destruction were assessed using the Health Assessment Questionnaire disability index (HAQ DI), the Disease Activity Score (DAS), and a modification of the sharp radiographic damage score, respectively. Multiple linear regression was used to model the data collected at 0, 3, 6, and 9 years after study start, to investigate which variables influenced functional capacity during the disease course. A general linear mixed model for longitudinal data, which included the variables identified as significant in the multiple linear regression models and several interaction terms between the variables, was run.\nRESULTS: On average, the functional capacity of the patients, as measured by the HAQ DI, worsened over the course of the disease after an initial improvement. After an initial reduction in the extent of disease activity, the mean DAS remained more or less stable over the course of the disease. The mean modified sharp joint damage score worsened over the course of the disease, with a slower progression rate later in the disease. In the multiple linear regression at 0, 3, and 6 years after study start, disease activity was found to be an important factor influencing functional capacity, and at 6 and 9 years, joint damage had an important effect on functional capacity. Furthermore, at 6 and 9 years, there was an interaction effect of joint destruction with disease activity. In the general linear mixed model, disease activity, joint damage, and an interaction effect of disease activity and joint damage were the main factors explaining functional capacity.\nCONCLUSION: The effect of disease activity and joint destruction on functional capacity changes over the course of the disease. In early RA, functional capacity is most associated with disease activity, and in late disease, with joint damage.", "publicationTitle": "Arthritis and Rheumatism", "publisher": "", "place": "", "date": "Sep 2001", "volume": "44", "issue": "9", "section": "", "partNumber": "", "partTitle": "", "pages": "2009-2017", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Arthritis Rheum.", "DOI": "10.1002/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L", "citationKey": "", "url": "", "accessDate": "", "PMID": "11592361", "PMCID": "", "ISSN": "0004-3591", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "eng", "libraryCatalog": "NCBI PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "Adult", "type": 1 }, { "tag": "Age Distribution", "type": 1 }, { "tag": "Aged", "type": 1 }, { "tag": "Arthritis, Rheumatoid", "type": 1 }, { "tag": "Disability Evaluation", "type": 1 }, { "tag": "Disease Progression", "type": 1 }, { "tag": "Female", "type": 1 }, { "tag": "Follow-Up Studies", "type": 1 }, { "tag": "Humans", "type": 1 }, { "tag": "Joints", "type": 1 }, { "tag": "Linear Models", "type": 1 }, { "tag": "Longitudinal Studies", "type": 1 }, { "tag": "Male", "type": 1 }, { "tag": "Middle Aged", "type": 1 }, { "tag": "Severity of Illness Index", "type": 1 }, { "tag": "Sex Distribution", "type": 1 } ], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-03T08:51:03Z", "dateModified": "2015-03-03T08:51:03Z" } }, { "key": "RTBQEREP", "version": 266, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/RTBQEREP", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/RTBQEREP", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/264915/items/TT472M6F", "type": "application/json" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } } }, "data": { "key": "RTBQEREP", "version": 266, "parentItem": "TT472M6F", "itemType": "attachment", "linkMode": "linked_url", "title": "PubMed entry", "accessDate": "2015-03-03T08:51:03Z", "url": "http://www.ncbi.nlm.nih.gov/pubmed/11592361", "note": "", "contentType": "text/html", "charset": "", "tags": [], "relations": {}, "dateAdded": "2015-03-03T08:51:03Z", "dateModified": "2015-03-03T08:51:03Z" } }, { "key": "IP6BFMDQ", "version": 265, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/IP6BFMDQ", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/IP6BFMDQ", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Lacroix et al.", "parsedDate": "2014-10-29", "numChildren": 0 }, "data": { "key": "IP6BFMDQ", "version": 265, "itemType": "journalArticle", "title": "Simultaneous Exposure–Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol", "creators": [ { "creatorType": "author", "firstName": "B D", "lastName": "Lacroix" }, { "creatorType": "author", "firstName": "M O", "lastName": "Karlsson" }, { "creatorType": "author", "firstName": "L E", "lastName": "Friberg" } ], "abstractNote": "", "publicationTitle": "CPT Pharmacometrics Syst. Pharmacol.", "publisher": "", "place": "", "date": "2014-10-29", "volume": "3", "issue": "10", "section": "", "partNumber": "", "partTitle": "", "pages": "e143", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1038/psp.2014.41", "citationKey": "", "url": "http://doi.wiley.com/10.1038/psp.2014.41", "accessDate": "2015-03-03T08:33:56Z", "PMID": "", "PMCID": "", "ISSN": "2163-8306", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-03T08:33:56Z", "dateModified": "2015-03-03T08:33:56Z" } }, { "key": "Z3W2MMGI", "version": 264, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/Z3W2MMGI", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/Z3W2MMGI", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Lacroix et al.", "parsedDate": "2009", "numChildren": 0 }, "data": { "key": "Z3W2MMGI", "version": 264, "itemType": "journalArticle", "title": "A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis", "creators": [ { "creatorType": "author", "firstName": "B D", "lastName": "Lacroix" }, { "creatorType": "author", "firstName": "M R", "lastName": "Lovern" }, { "creatorType": "author", "firstName": "A", "lastName": "Stockis" }, { "creatorType": "author", "firstName": "M L", "lastName": "Sargentini-Maier" }, { "creatorType": "author", "firstName": "M O", "lastName": "Karlsson" }, { "creatorType": "author", "firstName": "L E", "lastName": "Friberg" } ], "abstractNote": "", "publicationTitle": "Clinical Pharmacology & Therapeutics", "publisher": "", "place": "", "date": "10/2009", "volume": "86", "issue": "4", "section": "", "partNumber": "", "partTitle": "", "pages": "387-395", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1038/clpt.2009.136", "citationKey": "", "url": "http://doi.wiley.com/10.1038/clpt.2009.136", "accessDate": "2015-03-03T08:33:35Z", "PMID": "", "PMCID": "", "ISSN": "0009-9236, 1532-6535", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-03T08:33:35Z", "dateModified": "2015-03-03T08:33:35Z" } }, { "key": "BXXMVM2N", "version": 263, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/BXXMVM2N", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/BXXMVM2N", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Schipper et al.", "parsedDate": "2011-07-01", "numChildren": 0 }, "data": { "key": "BXXMVM2N", "version": 263, "itemType": "journalArticle", "title": "Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective", "creators": [ { "creatorType": "author", "firstName": "L. G.", "lastName": "Schipper" }, { "creatorType": "author", "firstName": "W.", "lastName": "Kievit" }, { "creatorType": "author", "firstName": "A. A.", "lastName": "den Broeder" }, { "creatorType": "author", "firstName": "M. A.", "lastName": "van der Laar" }, { "creatorType": "author", "firstName": "E. M. M.", "lastName": "Adang" }, { "creatorType": "author", "firstName": "J.", "lastName": "Fransen" }, { "creatorType": "author", "firstName": "P. L. C. M.", "lastName": "van Riel" } ], "abstractNote": "", "publicationTitle": "Rheumatology", "publisher": "", "place": "", "date": "2011-07-01", "volume": "50", "issue": "7", "section": "", "partNumber": "", "partTitle": "", "pages": "1320-1330", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1093/rheumatology/ker084", "citationKey": "", "url": "http://www.rheumatology.oxfordjournals.org/cgi/doi/10.1093/rheumatology/ker084", "accessDate": "2015-03-03T08:25:34Z", "PMID": "", "PMCID": "", "ISSN": "1462-0324, 1462-0332", "archive": "", "archiveLocation": "", "shortTitle": "Treatment strategies aiming at remission in early rheumatoid arthritis patients", "language": "en", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-03T08:25:34Z", "dateModified": "2015-03-03T08:25:34Z" } }, { "key": "NGHECN5X", "version": 262, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/NGHECN5X", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/NGHECN5X", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Welsing et al.", "parsedDate": "2004-12-15", "numChildren": 0 }, "data": { "key": "NGHECN5X", "version": 262, "itemType": "journalArticle", "title": "Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands: Cost Effectiveness of TNF-Blocking Treatment", "creators": [ { "creatorType": "author", "firstName": "Paco M. J.", "lastName": "Welsing" }, { "creatorType": "author", "firstName": "Johan L.", "lastName": "Severens" }, { "creatorType": "author", "firstName": "Margriet", "lastName": "Hartman" }, { "creatorType": "author", "firstName": "Piet L. C. M.", "lastName": "van Riel" }, { "creatorType": "author", "firstName": "Roland F. J. M.", "lastName": "Laan" } ], "abstractNote": "", "publicationTitle": "Arthritis Care & Research", "publisher": "", "place": "", "date": "2004-12-15", "volume": "51", "issue": "6", "section": "", "partNumber": "", "partTitle": "", "pages": "964-973", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1002/art.20843", "citationKey": "", "url": "http://doi.wiley.com/10.1002/art.20843", "accessDate": "2015-03-03T08:23:25Z", "PMID": "", "PMCID": "", "ISSN": "00043591", "archive": "", "archiveLocation": "", "shortTitle": "Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands", "language": "en", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-03T08:23:25Z", "dateModified": "2015-03-03T08:23:25Z" } }, { "key": "C9AV5NXN", "version": 261, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/C9AV5NXN", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/C9AV5NXN", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Lekander et al.", "parsedDate": "2013", "numChildren": 0 }, "data": { "key": "C9AV5NXN", "version": 261, "itemType": "journalArticle", "title": "The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice", "creators": [ { "creatorType": "author", "firstName": "Ingrid", "lastName": "Lekander" }, { "creatorType": "author", "firstName": "Fredrik", "lastName": "Borgström" }, { "creatorType": "author", "firstName": "Jörgen", "lastName": "Lysholm" }, { "creatorType": "author", "firstName": "Ronald F.", "lastName": "van Vollenhoven" }, { "creatorType": "author", "firstName": "Staffan", "lastName": "Lindblad" }, { "creatorType": "author", "firstName": "Pierre", "lastName": "Geborek" }, { "creatorType": "author", "firstName": "Gisela", "lastName": "Kobelt" } ], "abstractNote": "", "publicationTitle": "The European Journal of Health Economics", "publisher": "", "place": "", "date": "12/2013", "volume": "14", "issue": "6", "section": "", "partNumber": "", "partTitle": "", "pages": "863-873", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1007/s10198-012-0431-6", "citationKey": "", "url": "http://link.springer.com/10.1007/s10198-012-0431-6", "accessDate": "2015-03-03T08:14:16Z", "PMID": "", "PMCID": "", "ISSN": "1618-7598, 1618-7601", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "en", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-03T08:14:16Z", "dateModified": "2015-03-03T08:14:16Z" } }, { "key": "FDQNCW7R", "version": 287, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/FDQNCW7R", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/FDQNCW7R", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "lastModifiedByUser": { "id": 1843087, "username": "sgsteiger", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/sgsteiger", "type": "text/html" } } }, "creatorSummary": "Kobelt et al.", "parsedDate": "2011-07", "numChildren": 1 }, "data": { "key": "FDQNCW7R", "version": 287, "itemType": "journalArticle", "title": "Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment", "creators": [ { "creatorType": "author", "firstName": "Gisela", "lastName": "Kobelt" }, { "creatorType": "author", "firstName": "Ingrid", "lastName": "Lekander" }, { "creatorType": "author", "firstName": "Andrea", "lastName": "Lang" }, { "creatorType": "author", "firstName": "Bernd", "lastName": "Raffeiner" }, { "creatorType": "author", "firstName": "Costantino", "lastName": "Botsios" }, { "creatorType": "author", "firstName": "Pierre", "lastName": "Geborek" } ], "abstractNote": "OBJECTIVES: To explore the cost-effectiveness of early biologic treatment, followed by dose-reduction in the case of remission, of active rheumatoid arthritis (RA), compared with standard treatment with methotrexate (MTX) in Sweden.\nMETHODS: Effectiveness (function, disease activity, erosions) in early RA for both alternatives was taken from a clinical trial comparing etanercept (ETA) combined with MTX to MTX alone. Patients discontinuing treatment can switch to another or their first biologic treatment. For patients in remission (Disease Activity Score [DAS28] < 2.6), ETA is reduced to half the dose. Return to full dose occurs when DAS28 reaches ≥ 3.2 again. Costs and utilities by level of functional capacity from an observational study are used. The model is analyzed as a micro-simulation and results are presented from the societal perspective for Sweden, for 10 years; costs (€2008) and effects are discounted at 3 percent. Sensitivity analysis was performed for the perspective, the time horizon, switching, and dose-reduction.\nRESULTS: The main analysis conservatively assumes 50 percent switching at discontinuation. The cost per quality-adjusted life-year (QALY) gained with early ETA/MTX treatment is €13,500 (societal perspective, incremental cost of €15,500 and incremental QALYs of 1.15). With 75 percent switching, the cost per QALY gained was €10,400. Over 20 years, the cost per QALY gained was €8,200. Results were further sensitive to the time patients remained on half dose and the perspective. CONCLUSIONS AND POLICY IMPLICATIONS: This study combines clinical trial and clinical practice data to explore cost-effective treatment scenarios in early RA, including the use of biologics. Our results indicate that a situation where a considerable proportion of patients achieve remission, dose-adjustments will increase the cost-effectiveness of treatment.", "publicationTitle": "International Journal of Technology Assessment in Health Care", "publisher": "", "place": "", "date": "Jul 2011", "volume": "27", "issue": "3", "section": "", "partNumber": "", "partTitle": "", "pages": "193-200", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Int J Technol Assess Health Care", "DOI": "10.1017/S0266462311000195", "citationKey": "", "url": "", "accessDate": "", "PMID": "21736857", "PMCID": "", "ISSN": "1471-6348", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "eng", "libraryCatalog": "NCBI PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "Anti-Inflammatory Agents, Non-Steroidal", "type": 1 }, { "tag": "Arthritis, Rheumatoid", "type": 1 }, { "tag": "Cost-Benefit Analysis", "type": 1 }, { "tag": "Female", "type": 1 }, { "tag": "Humans", "type": 1 }, { "tag": "Immunoglobulin G", "type": 1 }, { "tag": "Male", "type": 1 }, { "tag": "Markov Chains", "type": 1 }, { "tag": "Middle Aged", "type": 1 }, { "tag": "Models, Economic", "type": 1 }, { "tag": "Questionnaires", "type": 1 }, { "tag": "Receptors, Tumor Necrosis Factor", "type": 1 }, { "tag": "Sweden", "type": 1 } ], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-02T17:05:54Z", "dateModified": "2015-03-02T17:05:54Z" } }, { "key": "2F7HRBPC", "version": 260, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/2F7HRBPC", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/2F7HRBPC", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/264915/items/FDQNCW7R", "type": "application/json" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } } }, "data": { "key": "2F7HRBPC", "version": 260, "parentItem": "FDQNCW7R", "itemType": "attachment", "linkMode": "linked_url", "title": "PubMed entry", "accessDate": "2015-03-02T17:05:54Z", "url": "http://www.ncbi.nlm.nih.gov/pubmed/21736857", "note": "", "contentType": "text/html", "charset": "", "tags": [], "relations": {}, "dateAdded": "2015-03-02T17:05:54Z", "dateModified": "2015-03-02T17:05:54Z" } }, { "key": "64FU4WKS", "version": 287, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/64FU4WKS", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/64FU4WKS", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "lastModifiedByUser": { "id": 1843087, "username": "sgsteiger", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/sgsteiger", "type": "text/html" } } }, "creatorSummary": "Barton et al.", "parsedDate": "2004-03", "numChildren": 1 }, "data": { "key": "64FU4WKS", "version": 287, "itemType": "journalArticle", "title": "The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis", "creators": [ { "creatorType": "author", "firstName": "P.", "lastName": "Barton" }, { "creatorType": "author", "firstName": "P.", "lastName": "Jobanputra" }, { "creatorType": "author", "firstName": "J.", "lastName": "Wilson" }, { "creatorType": "author", "firstName": "S.", "lastName": "Bryan" }, { "creatorType": "author", "firstName": "A.", "lastName": "Burls" } ], "abstractNote": "OBJECTIVES: To address the structural issues relating to mortality and quality of life (QoL) effects and to identify data on the general pattern of QoL of rheumatoid arthritis (RA) patients through a restructured and enhanced version of the Birmingham Preliminary Model (BPM).\nDATA SOURCES: Electronic databases and a postal survey of current UK rheumatological practice.\nREVIEW METHODS: The focus for this report was to evaluate two new drugs, etanercept and infliximab [antibodies against tumour necrosis factor (anti-TNFs)], for use in the treatment of RA using the Birmingham Rheumatoid Arthritis Model (BRAM). Having carried out a rapid systematic review of physician surveys of current disease-modifying antirheumatic drugs (DMARDs) usage patterns in adult patients with RA and a postal survey of consultant rheumatologists working in the UK, the drug sequences were then identified for the model. A series of analyses were then run using the model. The issue of specifying the correct comparison in the analysis being undertaken was investigated using two separate analyses: the situation of comparing anti-TNFs with placebo, and the comparison of a sequence using anti-TNFs with a sequence that represents current practice in the UK.\nRESULTS: Results from the survey of rheumatologists highlighted the fact that RA has different manifestations and responds to different agents in different patients, all of which makes any summary of practice difficult to achieve and open to the criticism of being an oversimplification. However, the findings generally agree with other surveys and trends observed, such as the increasing acceptance of methotrexate as first line drug of choice in patients with RA, especially if the disease is of an aggressive nature. The newer anti-TNF agents have also begun to be incorporated into use. The incremental cost-effectiveness ratios resulting from the use of an inappropriate comparator of placebo were consistently lower than in the base case where appropriate comparator drugs sequences are used. The focus of the BRAM on a drug sequence helped to avoid the incremental cost-effectiveness of new treatments appearing lower than they really are when inappropriate comparators are used. To test the effect on the analysis results of using the disease-modifying antirheumatic sequence that represents current UK practice, the BRAM was run for the strategies representing current UK practice. The results were not very different from the base-case results.\nCONCLUSIONS: The main achievement of this work was to bring about a more realistic modelling of real-life clinical pathways and events, as it has developed from the BPM to the BRAM. This has been brought about by overcoming structural and data limitations. In addition, the modelling approach reflected in the BRAM is applicable to other chronic conditions, especially those where a sequential approach to therapeutic options exists. The model has been successfully restructured so that different sequences of treatment can readily be considered, including the sequence that best represents current clinical practice in the UK. In addition, the flexibility inherent in using a modelling approach to consider these health policy questions has been demonstrated. One of the key uncertainties that can now be explored concerns the impact of new drugs on disease progression. Current evidence on this is weak, but should new agents demonstrate such a benefit then the BRAM may be a suitable vehicle through which to investigate the costs and full effects. Inevitably, there remain problems and limitations with the BRAM, but these are almost entirely data limitations. As data on these issues become available the BRAM provides a convenient tool through which reanalysis might be undertaken.", "publicationTitle": "Health Technology Assessment (Winchester, England)", "publisher": "", "place": "", "date": "Mar 2004", "volume": "8", "issue": "11", "section": "", "partNumber": "", "partTitle": "", "pages": "iii, 1-91", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Health Technol Assess", "DOI": "", "citationKey": "", "url": "", "accessDate": "", "PMID": "14982655", "PMCID": "", "ISSN": "1366-5278", "archive": "", "archiveLocation": "", "shortTitle": "The use of modelling to evaluate new drugs for patients with a chronic condition", "language": "eng", "libraryCatalog": "NCBI PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "Adolescent", "type": 1 }, { "tag": "Adult", "type": 1 }, { "tag": "Aged", "type": 1 }, { "tag": "Aged, 80 and over", "type": 1 }, { "tag": "Antibodies, Monoclonal", "type": 1 }, { "tag": "Antirheumatic Agents", "type": 1 }, { "tag": "Arthritis, Rheumatoid", "type": 1 }, { "tag": "Chronic Disease", "type": 1 }, { "tag": "Drug Evaluation", "type": 1 }, { "tag": "Female", "type": 1 }, { "tag": "Great Britain", "type": 1 }, { "tag": "Health Services Research", "type": 1 }, { "tag": "Humans", "type": 1 }, { "tag": "Immunoglobulin G", "type": 1 }, { "tag": "Male", "type": 1 }, { "tag": "Middle Aged", "type": 1 }, { "tag": "Receptors, Tumor Necrosis Factor", "type": 1 }, { "tag": "Treatment Outcome", "type": 1 }, { "tag": "Tumor Necrosis Factor-alpha", "type": 1 } ], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-02T16:03:38Z", "dateModified": "2015-03-02T16:03:38Z" } }, { "key": "IBZZ7TI2", "version": 259, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/IBZZ7TI2", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/IBZZ7TI2", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/264915/items/64FU4WKS", "type": "application/json" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } } }, "data": { "key": "IBZZ7TI2", "version": 259, "parentItem": "64FU4WKS", "itemType": "attachment", "linkMode": "linked_url", "title": "PubMed entry", "accessDate": "2015-03-02T16:03:38Z", "url": "http://www.ncbi.nlm.nih.gov/pubmed/14982655", "note": "", "contentType": "text/html", "charset": "", "tags": [], "relations": {}, "dateAdded": "2015-03-02T16:03:38Z", "dateModified": "2015-03-02T16:03:38Z" } }, { "key": "66XQ97X2", "version": 258, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/66XQ97X2", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/66XQ97X2", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Brennan", "parsedDate": "2004-01-01", "numChildren": 0 }, "data": { "key": "66XQ97X2", "version": 258, "itemType": "journalArticle", "title": "Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK", "creators": [ { "creatorType": "author", "firstName": "A.", "lastName": "Brennan" } ], "abstractNote": "", "publicationTitle": "Rheumatology", "publisher": "", "place": "", "date": "2004-01-01", "volume": "43", "issue": "1", "section": "", "partNumber": "", "partTitle": "", "pages": "62-72", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1093/rheumatology/keg451", "citationKey": "", "url": "http://www.rheumatology.oupjournals.org/cgi/doi/10.1093/rheumatology/keg451", "accessDate": "2015-03-02T15:15:48Z", "PMID": "", "PMCID": "", "ISSN": "1460-2172", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "en", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-02T15:15:48Z", "dateModified": "2015-03-02T15:15:48Z" } }, { "key": "V5N2ES6B", "version": 257, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/V5N2ES6B", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/V5N2ES6B", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "creatorSummary": "Tosh et al.", "parsedDate": "2011-09-01", "numChildren": 0 }, "data": { "key": "V5N2ES6B", "version": 257, "itemType": "journalArticle", "title": "The Sheffield rheumatoid arthritis health economic model", "creators": [ { "creatorType": "author", "firstName": "J.", "lastName": "Tosh" }, { "creatorType": "author", "firstName": "A.", "lastName": "Brennan" }, { "creatorType": "author", "firstName": "A.", "lastName": "Wailoo" }, { "creatorType": "author", "firstName": "N.", "lastName": "Bansback" } ], "abstractNote": "", "publicationTitle": "Rheumatology", "publisher": "", "place": "", "date": "2011-09-01", "volume": "50", "issue": "suppl 4", "section": "", "partNumber": "", "partTitle": "", "pages": "iv26-iv31", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1093/rheumatology/ker243", "citationKey": "", "url": "http://www.rheumatology.oxfordjournals.org/cgi/doi/10.1093/rheumatology/ker243", "accessDate": "2015-03-02T12:57:44Z", "PMID": "", "PMCID": "", "ISSN": "1462-0324, 1462-0332", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "en", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [ "8IQUUXCJ" ], "relations": {}, "dateAdded": "2015-03-02T12:57:44Z", "dateModified": "2015-03-02T12:57:44Z" } }, { "key": "4KPUBQGR", "version": 287, "library": { "type": "group", "id": 264915, "name": "ISPM_UniBe_GetReal", "links": { "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/264915/items/4KPUBQGR", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/ispm_unibe_getreal/items/4KPUBQGR", "type": "text/html" } }, "meta": { "createdByUser": { "id": 1901748, "username": "nhummel", "name": "Noemi Hummel", "links": { "alternate": { "href": "https://www.zotero.org/nhummel", "type": "text/html" } } }, "lastModifiedByUser": { "id": 1843087, "username": "sgsteiger", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/sgsteiger", "type": "text/html" } } }, "creatorSummary": "Finckh et al.", "parsedDate": "2009-11-03", "numChildren": 1 }, "data": { "key": "4KPUBQGR", "version": 287, "itemType": "journalArticle", "title": "Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis", "creators": [ { "creatorType": "author", "firstName": "Axel", "lastName": "Finckh" }, { "creatorType": "author", "firstName": "Nick", "lastName": "Bansback" }, { "creatorType": "author", "firstName": "Carlo A.", "lastName": "Marra" }, { "creatorType": "author", "firstName": "Aslam H.", "lastName": "Anis" }, { "creatorType": "author", "firstName": "Kaleb", "lastName": "Michaud" }, { "creatorType": "author", "firstName": "Stanley", "lastName": "Lubin" }, { "creatorType": "author", "firstName": "Marc", "lastName": "White" }, { "creatorType": "author", "firstName": "Sonia", "lastName": "Sizto" }, { "creatorType": "author", "firstName": "Matthew H.", "lastName": "Liang" } ], "abstractNote": "BACKGROUND: Long-term control or remission of rheumatoid arthritis (RA) may be possible with very early treatment. However, no optimal first therapeutic strategy has been determined.\nOBJECTIVE: To assess the potential cost-effectiveness of major therapeutic strategies for very early RA.\nDESIGN: Decision analytic model with probabilistic sensitivity analyses.\nDATA SOURCES: Published data, the National Data Bank for Rheumatic Diseases, and actual 2007 hospital costs.\nTARGET POPULATION: U.S. adults with very early RA (symptom duration